Recent insights into cutaneous immunization: How to vaccinate via the skin

Vaccine

Volumn 33, Issue 37, 2015, Pages 4663-4674

  Engelke, Laura ^a   Winter, Gerhard ^a   Hook, Sarah ^b   Engert, Julia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Dermal dendritic cell; DNA vaccination; Langerhans cell; Skin microporation; Transcutaneous vaccination; Vaccine adjuvant

Indexed keywords

DNA VACCINE; IMMUNOLOGICAL ADJUVANT; RNA VACCINE; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ARTICLE; CELL SUBPOPULATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENETIC IMMUNIZATION; GENETIC SKIN VACCINATION; HUMAN; JET INJECTION; MICRONEEDLE; NEEDLE FREE CUTANEOUS VACCINATION; NONHUMAN; PASSIVE IMMUNIZATION; POWDER INJECTION; PRIORITY JOURNAL; RNA IMMUNIZATION; SONOPORATION; STRATUM CORNEUM DISRUPTIVE APPROACH; THERMAL MICROPORATION TECHNOLOGY; TRANSDERMAL ELECTROPORATION; ULTRASOUND; VACCINATION; ADVERSE EFFECTS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MEDICAL RESEARCH; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS;

ADMINISTRATION, CUTANEOUS; BIOMEDICAL RESEARCH; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; VACCINES;

EID: 84940453177     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.012     Document Type: Article

References (223)

1. Stern A.M., Markel H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff (Millwood) 2005, 24:611-621.
2. Jenner E. An inquiry into the causes and effects of the variolae vaccinae: a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the Cow Pox 1798, Printed for the Author by Sampson Low, London.
3. Gothier D. Nadelfreie Injektionssysteme. TechnoPharm 2012, 2:68-76.
4. Pattanayak S., Arora D.D., Sehgal C.L., Raghavan N.G., Topa P.K., Subrahmanyam Y.K. Comparative studies of smallpox vaccination by the bifurcated needle and rotary lancet techniques. Bull World Health Organ 1970, 42:305-310.
5. Andersen P., Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005, 3:656-662.
6. BCG vaccine WHO position paper. Wkly Epidemiol Rec 2004, 79:27-38.
7. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
8. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
9. Karande P., Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol Eng 2010, 1:175-201.
10. Bal S.M., Ding Z., van Riet E., Jiskoot W., Bouwstra J.A. Advances in transcutaneous vaccine delivery: do all ways lead to Rome. J Control Release 2010, 148:266-282.
11. Prow T.W., Chen X., Prow N.A., Fernando G.J., Tan C.S., Raphael A.P., et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6:1776-1784.
12. Bangert C., Brunner P.M., Stingl G. Immune functions of the skin. Clin Dermatol 2011, 29:360-376.
13. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392.
14. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
15. Fernando G.J.P., Chen X., Primiero C.A., Yukiko S.R., Fairmaid E.J., Corbett H.J., et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release 2012, 159:215-221.
16. Kim Y.-C., Quan F.-S., Yoo D.-G., Compans R.W., Kang S.-M., Prausnitz M.R. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009, 27:6932-6938.
17. Kim Y.-C., Quan F.-S., Yoo D.-G., Compans R.W., Kang S.-M., Prausnitz M.R. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010, 201:190-198.
18. Chen D., Endres R., Maa Y.-F., Kensil C.R., Whitaker-Dowling P., Trichel A., et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 2003, 21:2830-2836.
19. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351:2295-2301.
20. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
21. Bernard K.W., Mallonee J., Wright J.C., Reid F.L., Makintubee S., Parker R.A., et al. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination. JAMA 1987, 257:1059-1063.
22. Das H.S., Sawant P., Shirhatti R.G., Vyas K., Vispute S., Dhadphale S., et al. Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among health care workers. Trop Gastroenterol 2002, 23:120-121.
23. Xiao G., Li X., Kumar A., Cui Z. Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses. Eur J Pharm Biopharm 2012, 82:212-217.
24. Bramson J., Dayball K., Evelegh C., Wan Y.H., Page D., Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther 2003, 10:251-260.
25. Chen D., Periwal S.B., Larrivee K., Zuleger C., Erickson C.A., Endres R.L., et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 2001, 75:7956-7965.
26. Yagi H., Hashizume H., Horibe T., Yoshinari Y., Hata M., Ohshima A., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006, 66:10136-10144.
27. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Investig 2004, 113:998-1007.
28. Weniger B.G., Papania M.J. Alternative vaccine delivery methods. Vaccines 2013, 1200-1231. Elsevier/Saunders, Philadelphia, Available at: http://bit.ly/Vaccines6thChap61a. 6 ed. S.A. Plotkin, W. Orenstein, P.A. Offit (Eds.).
29. Glenn G.M., Scharton-Kersten T., Vasselll R., Matyas G.R., Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999, 67:1100-1106.
30. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000, 6:1403-1406.
31. Ishii Y., Nakae T., Sakamoto F., Matsuo K., Matsuo K., Quan Y.-S., et al. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Release 2008, 131:113-120.
32. Strid J., Hourihane J., Kimber I., Callard R., Strobel S. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol 2004, 34:2100-2109.
33. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25:3684-3691.
34. Watabe S., Xin K.-Q., Ihata A., Liu L.-J., Honsho A., Aoki I., et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 2001, 19:4434-4444.
35. Kis E.E., Winter G., Myschik J. Devices for intradermal vaccination. Vaccine 2012, 30:523-538.
36. Banga A.K. Microporation applications for enhancing drug delivery. Expert Opin Drug Deliv 2009, 6:343-354.
37. Denet A.-R., Vanbever R., Préat V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev 2004, 56:659-674.
38. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2:251-262.
39. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
40. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
41. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997, 15:821-850.
42. Lin M.L., Zhan Y., Villadangos J.A., Lew A.M. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 2008, 86:353-362.
43. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010, 207:1247-1260.
44. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004, 22:817-890.
45. Moody D.B., Porcelli S.A. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol 2003, 3:11-22.
46. Godfrey D.I., Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig 2004, 114:1379-1388.
47. Gillessen S., Naumov Y.N., Nieuwenhuis E.E., Exley M.A., Lee F.S., Mach N., et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 2003, 100:8874-8879.
48. Peiser M., Grutzkau A., Wanner R., Kolde G. CD1a and CD1c cell sorting yields a homogeneous population of immature human Langerhans cells. J Immunol Methods 2003, 279:41-53.
49. Ochoa M.T., Loncaric A., Krutzik S.R., Becker T.C., Modlin R.L. Dermal dendritic cells comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J Investig Dermatol 2008, 128:2225-2231.
50. Gerlini G., Hefti H.P., Kleinhans M., Nickoloff B.J., Burg G., Nestle F.O. Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Investig Dermatol 2001, 117:576-582.
51. Teunissen M.B., Haniffa M., Collin M.P. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr Top Microbiol Immunol 2012, 351:25-76.
52. Kaech S.M., Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001, 2:415-422.
53. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-747.
54. Luckheeram R.V., Zhou R., Verma A.D., Xia B. CD4(+)T cells: differentiation and functions. Clin Dev Immunol 2012, 2012:925135.
55. Yuseff M.I., Pierobon P., Reversat A., Lennon-Dumenil A.M. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol 2013, 13:475-486.
56. McHeyzer-Williams M.G., Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999, 11:172-179.
57. Liew F.Y. TH1 and TH2 cells: a historical perspective. Nat Rev Immunol 2002, 2:55-60.
58. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
59. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
60. Romagnani S., Maggi E., Liotta F., Cosmi L., Annunziato F. Properties and origin of human Th17 cells. Mol Immunol 2009, 47:3-7.
61. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
62. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871.
63. Clark R.A., Chong B., Mirchandani N., Brinster N.K., Yamanaka K., Dowgiert R.K., et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006, 176:4431-4439.
64. Ginhoux F., Ng L.G., Merad M. Understanding the murine cutaneous dendritic cell network to improve intradermal vaccination strategies. Curr Top Microbiol Immunol 2012, 351:1-24.
65. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008, 8:935-947.
66. Ginhoux F., Liu K., Helft J., Bogunovic M., Greter M., Hashimoto D., et al. The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med 2009, 206:3115-3130.
67. Bursch L.S., Wang L., Igyarto B., Kissenpfennig A., Malissen B., Kaplan D.H., et al. Identification of a novel population of Langerin+ dendritic cells. J Exp Med 2007, 204:3147-3156.
68. Henri S., Poulin L.F., Tamoutounour S., Ardouin L., Guilliams M., de Bovis B., et al. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med 2010, 207:189-206.
69. Bedoui S., Whitney P.G., Waithman J., Eidsmo L., Wakim L., Caminschi I., et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 2009, 10:488-495.
70. McLachlan J.B., Catron D.M., Moon J.J., Jenkins M.K. Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 2009, 30:277-288.
71. Nagao K., Ginhoux F., Leitner W.W., Motegi S., Bennett C.L., Clausen B.E., et al. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci USA 2009, 106:3312-3317.
72. Nestle F.O., Zheng X.G., Thompson C.B., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993, 151:6535-6545.
73. Haniffa M., Ginhoux F., Wang X.N., Bigley V., Abel M., Dimmick I., et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med 2009, 206:371-385.
74. Haniffa M., Shin A., Bigley V., McGovern N., Teo P., See P., et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012, 37:60-73.
75. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., et al. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol 2009, 70:281-288.
76. Caux C., Massacrier C., Vanbervliet B., Dubois B., Durand I., Cella M., et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997, 90:1458-1470.
77. Seneschal J., Clark R.A., Gehad A., Baecher-Allan C.M., Kupper T.S. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 2012, 36:873-884.
78. van der Aar A.M., de Groot R., Sanchez-Hernandez M., Taanman E.W., van Lier R.A., Teunissen M.B., et al. Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses. J Immunol 2011, 187:3488-3492.
79. Mathers A.R., Janelsins B.M., Rubin J.P., Tkacheva O.A., Shufesky W.J., Watkins S.C., et al. Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. J Immunol 2009, 182:921-933.
80. Bronaugh R.L., Stewart R.F., Congdon E.R. Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol Appl Pharmacol 1982, 62:481-488.
81. Scharton-Kersten T., Yu J.-m., Vassell R., O'Hagan D., Alving C.R., Glenn G.M. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000, 68:5306-5313.
82. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature 1998, 391:851-852.
83. Cui Z., Mumper R.J. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm 2003, 55:11-18.
84. Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C.D., Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010, 385:187-193.
85. Ding Z., Bal S., Romeijn S., Kersten G.A., Jiskoot W., Bouwstra J. Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharm Res 2011, 28:145-158.
86. Hammond S.A., Walwender D., Alving C.R., Glenn G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine 2001, 19:2701-2707.
87. Kahlon R., Hu Y., Orteu C.H., Kifayet A., Trudeau J.D., Tan R., et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 2003, 21:2890-2899.
88. Chen D., Erickson C.A., Endres R.L., Periwal S.B., Chu Q., Shu C., et al. Adjuvantation of epidermal powder immunization. Vaccine 2001, 19:2908-2917.
89. Weeratna R.D., Makinen S.R., McCluskie M.J., Davis H.L. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005, 23:5263-5270.
90. Alving C.R., Peachman K.K., Rao M., Reed S.G. Adjuvants for human vaccines. Curr Opin Immunol 2012, 24:310-315.
91. Bauer S., Kirschning C.J., Häcker H., Redecke V., Hausmann S., Akira S., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001, 98:9237-9242.
92. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001, 167:3555-3558.
93. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
94. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 2002, 85:247-262.
95. Schirmbeck R., Reimann J. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 2001, 44:115-123.
96. Warger T., Rechtsteiner G., Schmid B., Osterloh P., Schild H., Radsak M. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allergy Immunol 2007, 32:57-65.
97. DeMuth P.C., Min Y., Irvine D.J., Hammond P.T. Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization. Adv Healthc Mater 2014, 3:47-58.
98. DeMuth P.C., Garcia-Beltran W.F., Ai-Ling M.L., Hammond P.T., Irvine D.J. Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination. Adv Funct Mater 2013, 23:161-172.
99. Stein P., Rechtsteiner G., Warger T., Bopp T., Fuhr T., Prufer S., et al. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin. J Investig Dermatol 2011, 131:211-219.
100. Slade H.B., Owens M.L., Tomai M.A., Miller R.L. Imiquimod 5% cream (Aldara™). Expert Opin Investig Drugs 1998, 7:437-449.
101. Choi M.J., Maibach H.I. Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 2003, 16:271-282.
102. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci USA 2009, 106:18936-18941.
103. Brindle R.J., Morris C.A., Berger R., Kurtz J.B. Inadequate response to intradermal hepatitis A vaccine. Vaccine 1994, 12:483-484.
104. Carlsson U., Brudin L., Eliasson I., Hansson B.G., Hepatitis A vaccination by intracutaneous low dose administration: a less expensive alternative. Scand J Infect Dis 1996, 28:435-438.
105. Vogelbruch M., Nuss B., Korner M., Kapp A., Kiehl P., Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000, 55:883-887.
106. Canter J., Mackey K., Good L.S., Roberto R.R., Chin J., Bond W.W., et al. An outbreak of hepatitis b associated with jet injections in a weight reduction clinic. Arch Intern Med 1990, 150:1923-1927.
107. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5:905-916.
108. Arora A., Prausnitz M.R., Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm 2008, 364:227-236.
109. Baxter J., Mitragotri S. Jet-induced skin puncture and its impact on needle-free jet injections: experimental studies and a predictive model. J Control Release 2005, 106:361-373.
110. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006, 5:543-548.
111. Stachowiak J.C., Li T.H., Arora A., Mitragotri S., Fletcher D.A. Dynamic control of needle-free jet injection. J Control Release 2009, 135:104-112.
112. Arora A., Hakim I., Baxter J., Rathnasingham R., Srinivasan R., Fletcher D.A., et al. Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc Natl Acad Sci USA 2007, 104:4255-4260.
113. Stachowiak J.C., von Muhlen M.G., Li T.H., Jalilian L., Parekh S.H., Fletcher D.A. Piezoelectric control of needle-free transdermal drug delivery. J Control Release 2007, 124:88-97.
114. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996, 2:1122-1128.
115. Kendall M., Mitchell T., Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J Biomech 2004, 37:1733-1741.
116. Chen D., Endres R.L., Erickson C.A., Weis K.F., McGregor M.W., Kawaoka Y., et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000, 6:1187-1190.
117. Mulholland W.J., Kendall M.A.F., White N., Bellhouse B.J. Characterization of powdered epidermal vaccine delivery with multiphoton microscopy. Phys Med Biol 2004, 49:5043-5058.
118. Kendall M.A.F. The delivery of particulate vaccines and drugs to human skin with a practical, hand-held shock tube-based system. Shock Waves 2002, 12:23-30.
119. Liu J., Hogan N.C., Hunter I.W. Intradermal needle-free powdered drug injection by a helium-powered device. Conf Proc IEEE Eng Med Biol Soc 2012, 2012:2068-2071.
120. Chen D., Maa Y.-F., Haynes J.R. Needle-free epidermal powder immunization. Expert Rev Vaccines 2002, 1:265-276.
121. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19:764-778.
122. Loudon P.T., Yager E.J., Lynch D.T., Narendran A., Stagnar C., Franchini A.M., et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS ONE 2010, 5:e11021.
123. Chen D., Zuleger C., Chu Q., Maa Y.-F., Osorio J., Payne L.G. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res Hum Retrovir 2004, 18:715-722.
124. Goudy K.S., Wang B., Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin Immunol 2008, 129:49-57.
125. Deng Y., Mathaes R., Winter G., Engert J. Encapsulation of antigen-loaded silica nanoparticles into microparticles for intradermal powder injection. Eur J Pharm Sci 2014, 63:154-166.
126. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat Biotechnol 2008, 26:1261-1268.
127. Kim Y.-C., Park J.-H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012, 64:1547-1568.
128. Donnelly R.F., Singh T.R.R., Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 2010, 17:187-207.
129. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004, 56:581-587.
130. Hiraishi Y., Nakagawa T., Quan Y.-S., Kamiyama F., Hirobe S., Okada N., et al. Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. Int J Pharm 2013, 441(1-2):570-579.
131. Hirobe S., Azukizawa H., Matsuo K., Zhai Y., Quan Y.-S., Kamiyama F., et al. Development and clinical study of a self-dissolving microneedle patch for transcutaneous immunization device. Pharm Res 2013, 30:2664-2674.
132. Ding Z., Verbaan F.J., Bivas-Benita M., Bungener L., Huckriede A., van den Berg D.J., et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release 2009, 136:71-78.
133. Levin Y., Kochba E., Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same. Vaccine 2014, 32:4249-4252.
134. The University of Hong Kong Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device 2010, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01049490 [accessed 08.01.15]. Report No.: NCT01049490.
135. The University of Hong Kong VZV Vaccine for Hematopoietic Stem Cell Transplantation (VZIDST) 2014, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02329457 [accessed 08.01.15]. Report No.: NCT02329457.
136. Elvidge S. Merck tests needle-free vaccines. Nat Biotechnol 2012, 30:1155.
137. Vaxxas Inc. Vaxxas initiates program with Merck to optimize delivery of next generation vaccines utilizing novel mechanism for immune system activation. Cambridge, MA, USA/Brisbane, QLD, Australia 2012, Available at: http://www.vaxxas.com/news/vaxxas-initiates-program-with-merck-to-optimize-delivery-of-next-generation-vaccines/ [accessed 05.03.13].
138. Vaxxas Inc. Vaxxas initiates research project on advancing next generation technology for polio vaccine delivery. Brisbane, QLD, Australia/Cambridge, MA, USA 2014, Available at: http://www.vaxxas.com/news/vaxxas-initiates-research-project-on-advancing-next-generation-technology-for-polio-vaccine-delivery/ [accessed 04.10.14].
139. Zhu Q., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA 2009, 106:7968-7973.
140. Gill H.S., Prausnitz M.R. Coated microneedles for transdermal delivery. J Control Release 2007, 117:227-237.
141. Lee J.W., Park J.-H., Prausnitz M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008, 29:2113-2124.
142. Park J.-H., Lee J.-W., Kim Y.-C., Prausnitz M.R. The effect of heat on skin permeability. Int J Pharm 2008, 359:94-103.
143. Eppstein, JA. Microporation of tissue for delivery of bioactive agents. United States: Altea Technologies, Inc., assignee. Pat. 6527716; 2003.
144. Badkar A., Smith A., Eppstein J., Banga A. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm Res 2007, 24:1389-1395.
145. Sintov A.C., Krymberk I., Daniel D., Hannan T., Sohn Ze Levin G. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J Control Release 2003, 89:311-320.
146. Levin G., Gershonowitz A., Sacks H., Stern M., Sherman A., Rudaev S., et al. Transdermal delivery of human growth hormone through RF-microchannels. Pharm Res 2005, 22:550-555.
147. Avrahami, Z. Transdermal drug delivery and analyte extraction. United States: Elecsys Ltd., assignee. Pat. 6148232; 2000.
148. Walsh J.T., Deutsch T.F. Er:YAG laser ablation of tissue: measurement of ablation rates. Lasers Surg Med 1989, 9:327-337.
149. Weiss R., Hessenberger M., Kitzmüller S., Bach D., Weinberger E.E., Krautgartner W.D., et al. Transcutaneous vaccination via laser microporation. J Control Release 2012, 162:391-399.
150. Vodopyanov K.L. Bleaching of water by intense light at the maximum of the λ=3μm absorption band. J Exp Theor Phys 1990, 70:114-121.
151. Yu J., Kalaria D.R., Kalia Y.N. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J Control Release 2011, 156:53-59.
152. Stern, M, Levin, G. Transdermal delivery system for dried particulate or lyophilized medications. United States: TransPharma Medical Ltd., assignee. Pat. 7363075; 2008.
153. Hessenberger M., Weiss R., Weinberger E.E., Boehler C., Thalhamer J., Scheiblhofer S. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores. Vaccine 2013, 31(34):3427-3434.
154. Genina E.A., Bashkatov A.N., Dolotov L.E., Maslyakova G.N., Kochubey V.I., Yaroslavsky I.V., et al. Transcutaneous delivery of micro- and nanoparticles with laser microporation. J Biomed Opt 2013, 18:111406.
155. Misra A., Ganga S., Upadhyay P. Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 1999, 18:517-523.
156. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982, 1:841-845.
157. Chu G., Hayakawa H., Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res 1987, 15:1311-1326.
158. Pliquett U.F., Vanbever R., Preat V., Weaver J.C. Local transport regions (LTRs) in human stratum corneum due to long and short 'high voltage' pulses. Bioeletrochem Bioenerg 1998, 47:151-161.
159. Zhao Y.L., Murthy S.N., Manjili M.H., Guan L.J., Sen A., Hui S.W. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 2006, 24:1282-1290.
160. Tezel A., Paliwal S., Shen Z., Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005, 23:3800-3807.
161. Kushner J.I.V., Kim D., So P.T.C., Blankschtein D., Langer R.S. Dual-channel two-photon microscopy study of transdermal transport in skin treated with low-frequency ultrasound and a chemical enhancer. J Investig Dermatol 2007, 127:2832-2846.
162. Tezel A., Dokka S., Kelly S., Hardee G.E., Mitragotri S. Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis. Pharm Res 2004, 21:2219-2225.
163. Mitragotri S., Blankschtein D., Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharm Res 1996, 13:411-420.
164. Dahlan A., Alpar H.O., Stickings P., Sesardic D., Murdan S. Transcutaneous immunisation assisted by low-frequency ultrasound. Int J Pharm 2009, 368:123-128.
165. Choi E.H., Kim M.J., Yeh B.-I., Ahn S.K., Lee S.H. Iontophoresis and sonophoresis stimulate epidermal cytokine expression at energies that do not provoke a barrier abnormality: lamellar body secretion and cytokine expression are linked to altered epidermal calcium levels. J Investig Dermatol 2003, 121:1138-1144.
166. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001, 14:101-114.
167. Eypper E.H., Johnson P.V., Purro E.I., Hohmann E.L. Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant. Vaccine 2013, 31:3257-3261.
168. Sloat B.R., Kiguchi K., Xiao G., DiGiovanni J., Maury W., Cui Z. Transcutaneous DNA immunization following waxing-based hair depilation. J Control Release 2012, 157:94-102.
169. Bos J.D., Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000, 9:165-169.
170. Naito S., Maeyama J.-i., Mizukami T., Takahashi M., Hamaguchi I., Yamaguchi K. Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant. Vaccine 2007, 25:8762-8770.
171. Matsuo K., Ishii Y., Kawai Y., Saiba Y., Quan Y.S., Kamiyama F., et al. Analysis of transcutaneous antigenic protein delivery by a hydrogel patch formulation. J Pharm Sci 2013, 102:1936-1947.
172. Hirobe S., Matsuo K., Quan Y.S., Kamiyama F., Morito H., Asada H., et al. Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 2012, 30:1847-1854.
173. Mittal A., Raber A.S., Schaefer U.F., Weissmann S., Ebensen T., Schulze K., et al. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 2013, 31:3442-3451.
174. Cheng J.-Y., Huang H.-N., Tseng W.-C., Li T.-L., Chan Y.-L., Cheng K.-C., et al. Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection. J Control Release 2009, 135:242-249.
175. Gupta P.N., Mishra V., Rawat A., Dubey P., Mahor S., Jain S., et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 2005, 293:73-82.
176. Mishra D., Dubey V., Asthana A., Saraf D.K., Jain N.K. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 2006, 24:4847-4855.
177. Mishra D., Mishra P.K., Dubey V., Nahar M., Dabadghao S., Jain N.K. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008, 33:424-433.
178. Rattanapak T., Birchall J., Young K., Ishii M., Meglinski I., Rades T., et al. Transcutaneous immunization using microneedles and cubosomes: mechanistic investigations using Optical Coherence Tomography and Two-Photon Microscopy. J Control Release 2013, 172:894-903.
179. Mishra V., Mahor S., Rawat A., Dubey P., Gupta P.N., Singh P., et al. Development of novel fusogenic vesosomes for transcutaneous immunization. Vaccine 2006, 24:5559-5570.
180. Haensler J., Verdelet C., Sanchez V., Girerd-Chambaz Y., Bonnin A., Trannoy E., et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999, 17:628-638.
181. Cui Z., Baizer L., Mumper R.J. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 2003, 102:105-115.
182. Epstein J.E., Gorak E.J., Charoenvit Y., Wang R., Freydberg N., Osinowo O., et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002, 13:1551-1560.
183. Brave A., Ljungberg K., Boberg A., Rollman E., Isaguliants M., Lundgren B., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005, 12:1197-1205.
184. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 1998, 72:1491-1496.
185. ® system. Vaccine 1998, 16:394-398.
186. Lodmell D.L., Parnell M.J., Bailey J.R., Ewalt L.C., Hanlon C.A. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 2001, 20:838-844.
187. Gill H.S., Soderholm J., Prausnitz M.R., Sallberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 2010, 17:811-814.
188. Wang J., Hu J.-h., Li F.-q., Liu G.-z., Zhu Q.-g., Liu J.-y., et al. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp Dermatol 2007, 16:724-729.
189. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002, 8:415-419.
190. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011, 23:421-429.
191. Hallengard D., Brave A., Isaguliants M., Blomberg P., Enger J., Stout R., et al. A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther 2012, 10:5.
192. Selby M., Goldbeck C., Pertile T., Walsh R., Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000, 83:147-152.
193. Oosterhuis K., van den Berg J.H., Schumacher T.N., Haanen J.B. DNA vaccines and intradermal vaccination by DNA tattooing. Curr Top Microbiol Immunol 2012, 351:221-250.
194. Bins A.D., Jorritsma A., Wolkers M.C., Hung C.F., Wu T.C., Schumacher T.N., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005, 11:899-904.
195. Pokorna D., Rubio I., Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008, 6:4.
196. Verstrepen B.E., Bins A.D., Rollier C.S., Mooij P., Koopman G., Sheppard N.C., et al. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 2008, 26:3346-3351.
197. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998, 188:1075-1082.
198. van den Berg J.H., Nujien B., Beijnen J.H., Vincent A., van Tinteren H., Kluge J., et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009, 20:181-189.
199. Cho J.H., Youn J.W., Sung Y.C. Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J Immunol 2001, 167:5549-5557.
200. Bins A.D., Wolkers M.C., van den Boom M.D., Haanen J.B., Schumacher T.N. In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 2007, 179:2126-2133.
201. Matsuo K., Okamoto H., Kawai Y., Quan Y.-S., Kamiyama F., Hirobe S., et al. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease. J Neuroimmunol 2014, 266:1-11.
202. Bachhav Y.G., Heinrich A., Kalia Y.N. Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technology. Eur J Pharm Biopharm 2013, 84:355-364.
203. Matsuo K., Ishii Y., Quan Y.-S., Kamiyama F., Mukai Y., Yoshioka Y., et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J Control Release 2011, 149:15-20.
204. van Damme P. A study to assess the acceptability and usability of a new device for intradermal vaccination 2013, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01963338 [accessed 08.01.15]. Report No.: NCT01963338.
205. Immunomic Therapeutics Inc. A safety and immunogenicity phase IC study of CryJ2 -DNA-LAMP plasmid vaccine for assessment of intradermal (ID) route of administration using the biojector 2000 device 2014, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02146781 [accessed 08.01.15]. Report No.: NCT02146781.
206. Icardi G., Orsi A., Ceravolo A., Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum Vaccines Immunother 2012, 8:67-75.
207. Medgadget L.L.C. Sanofi Pasteur's Fluzone intradermal flu vaccine approved in U.S. 2011, Available at: http://www.medgadget.com/2011/05/sanofi_pasteurs_fluzone_intradermal_flu_vaccine_approved_in_us.html [accessed 17.10.14].
208. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
209. Zehrung D., Jarrahian C., Wales A. Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 2013, 31:3392-3395.
210. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
211. PharmaJet Inc. Inactivated Influenza Via Jet Injection (IIJI) 2014, National Library of Medicine (US), Bethesda, MD):, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/show/NCT02290691 [accessed 08.01.15]. Report No.: NCT02290691.
212. ® with or without ID Derma Vax™ electroporation followed by IM MVA boosting in healthy volunteers in Tanzania and Mozambique (TaMoVac II) 2012, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01697007 [accessed 08.01.15]. Report No.: NCT01697007.
213. Serum Institute of India Limited Safety and immunogenicity of MMR vaccine by DSJI to that by needle-syringe in 15-18 months old children 2014, National Library of Medicine (US), Bethesda, MD, In: clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02253407 [accessed 08.01.15]. Report No.: NCT02253407.
214. ® influenza vaccine with PharmaJet's needle-free injector. King of Prussia, PA/Golden, CO, USA 2014, Available at: http://pharmajet.com/fda-approves-afluria-influenza-vaccine-pharmajets-needle-free-injector/ [accessed 0510.14].
215. Pharmajet Inc. 510(k) Premarket Notification - Pharmajet Stratis Needle-Free Injection System 2011, U.S. Food and Drug Administration, Silver Spring, MD, In: http://www.fda.gov/. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K111517.pdf [accessed 26.03.15]. Report No: K111517.
216. ® 2000 Needle-Free Injection Management System (B2000) 2012, U.S. Food and Drug Administration, Silver Spring, MD, In: www.fda.gov. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf12/k121270.pdf [accessed 06.03.15]. Report No.: K121270.
217. ® Needle-Free Injection System 2009, U.S. Food and Drug Administration, Silver Sping, MD, In: www.fda.gov. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K090959.pdf [accessed 06.03.15]. Report No.: K090959.
218. Avant Medical Corporation. 510(k) Premarket Notification - Avant Guardian 101 2003, U.S. Food and Drug Administration, Silver Sping, MD, In: www.fda.gov. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf2/k024018.pdf [accessed 06.03.15]. Report No.: K024018.
219. BioValve Technologies Inc. 510(k) Premarket Notification - Mini-Ject Needlefree Injection System 2004, U.S. Food and Drug Administration, Silver Spring, MD, In: www.fda.gov. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf3/k032976.pdf [accessed 06.03.15]. Report No.: K032976.
220. Rosch AG Medizintechnik 510(k) Premarket Notification - INJEX needle-free injection system Extra, ROJEX needle-free injection system Extra 2002, U.S. Food and Drug Administration, Silver Sping, MD, In: www.fda.gov. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf2/K020786.pdf [accessed 06.03.15]. Report No.: K020786.
221. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
222. Bakari M., Aboud S., Nilsson C., Francis J., Buma D., Moshiro C., et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29:8417-8428.
223. Joachim A., Nilsson C., Aboud S., Lyamuya E.F., Robb M., Marovich M., et al. Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. Retrovirology 2012, 9. O53-O.